Three Peaks Capital Management’s Integra LifeSciences IART Stock Holding History

Three Peaks Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-56,822	Closed	-$3.66M	–	146
2018 Q2	$3.66M	Buy	+56,822	New	+$3.52M	0.74%	68

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Three Peaks Capital Management's IART Position: Q3 2018 in Review

Three Peaks Capital Management sold out of Integra LifeSciences (IART) in Q3 2018, closing a stake of 56,822 shares — an estimated $3.66M sold.

Three Peaks Capital Management first reported a position in IART in Q2 2018 and held it in 1 quarter. The position peaked at $3.66M in Q2 2018. 249 funds tracked by Wall St. Rank hold IART as of Q3 2018.

Three Peaks Capital Management reported no remaining Integra LifeSciences position as of Q3 2018 after selling out during the quarter.
Three Peaks Capital Management sold 56,822 Integra LifeSciences shares in Q3 2018, an estimated $3.66M.
Three Peaks Capital Management first reported a position in Integra LifeSciences in Q2 2018 and held it in 1 quarter.
Three Peaks Capital Management's Integra LifeSciences position peaked at $3.66M in Q2 2018.
249 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2018.

Based on Three Peaks Capital Management's 13F filing for Q3 2018, filed 23 Oct 2018.